ES2194320T3 - Sustancias naturales antivirales o antitumorales y uso de las mismas. - Google Patents
Sustancias naturales antivirales o antitumorales y uso de las mismas.Info
- Publication number
- ES2194320T3 ES2194320T3 ES98923089T ES98923089T ES2194320T3 ES 2194320 T3 ES2194320 T3 ES 2194320T3 ES 98923089 T ES98923089 T ES 98923089T ES 98923089 T ES98923089 T ES 98923089T ES 2194320 T3 ES2194320 T3 ES 2194320T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- represented
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 abstract 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000003327 cancerostatic effect Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención describe sustancias eficaces contra tumores y virus en los que los agentes convencionales antitumorales y agentes antivirales muestran solamente efectos insuficientes, y que tienen efectos carcinostáticos y efectos antivirales en varios tumores resistentes así como un efecto secundario reducido tal como las células humanas normales que no se han deteriorado.La presente invención se refiere a una sustancia antitumoral o antiviral representada por la fórmula (1)*fórmula*en la que R1 representa un a base de ácido nucleico representada por una fórmula específica, y R2 representa un átomo de hidrógeno, un grupo hidroxilo o un grupo metoxi, o una sal farmacéuticamente aceptable de los mismos.La presente invención también se refiere a un procedimiento para la preparación de una sustancia representada por la fórmula (1) o una sal farmacéuticamente aceptable de la misma, en la que se cultiva la célula NS que tiene la capacidad de producir el compuesto representado en la fórmula(1), el compuesto representado por la fórmula (1) se recoge del cultivo líquido y si es necesario el compuesto se convierte en una sal farmacéuticamente aceptable del mismo.Además, también se describe un compuesto farmacéutico que comprende el compuesto descrito anteriormente como ingrediente eficaz, y célula supresora natural humana positivo -CD57 y fuertemente positivo -HLA.DR-
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15932197 | 1997-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2194320T3 true ES2194320T3 (es) | 2003-11-16 |
Family
ID=15691258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98923089T Expired - Lifetime ES2194320T3 (es) | 1997-06-03 | 1998-06-02 | Sustancias naturales antivirales o antitumorales y uso de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6498149B1 (es) |
| EP (1) | EP0997473B1 (es) |
| JP (1) | JP3193061B2 (es) |
| KR (1) | KR100404630B1 (es) |
| CN (2) | CN1292073C (es) |
| AT (1) | ATE236922T1 (es) |
| AU (1) | AU754370B2 (es) |
| CA (1) | CA2294158C (es) |
| DE (1) | DE69813231T2 (es) |
| ES (1) | ES2194320T3 (es) |
| RU (1) | RU2205010C2 (es) |
| WO (1) | WO1998055493A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1098355C (zh) * | 2000-09-12 | 2003-01-08 | 华东理工大学 | 一种乙酰短杆菌及以该菌种为酶源制备5－氟尿苷的方法 |
| SK286630B6 (sk) * | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| RU2300384C2 (ru) * | 2005-01-31 | 2007-06-10 | Юрий Евгеньевич Бурда | Вещество, обладающее противовоспалительной, иммуномодулирующей и ранозаживляющей активностью |
| PT1962808E (pt) * | 2005-12-14 | 2010-10-29 | Hoffmann La Roche | Formulação de precursor de fármaco para o hcv |
| US7906518B2 (en) | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
| BRPI0713902A2 (pt) | 2006-06-27 | 2012-11-27 | Biovitrum Ab | compostos terapêuticos |
| WO2009042767A1 (en) * | 2007-09-26 | 2009-04-02 | Mount Sinai School Of Medicine | Azacytidine analogues and uses thereof |
| FI20096394A0 (fi) | 2009-12-23 | 2009-12-23 | Valtion Teknillinen | Tunkeutumisen havaitseminen viestintäverkoissa |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4071680A (en) * | 1976-12-20 | 1978-01-31 | Hoffmann-La Roche Inc. | 5'-Deoxy-5-fluoropyrimidine nucleosides |
| JPS54140710A (en) * | 1978-03-10 | 1979-11-01 | Mitsui Toatsu Chem Inc | Anti-tumor substance and its preparation |
| JPS54129131A (en) * | 1978-03-27 | 1979-10-06 | Taiho Pharmaceutical Co Ltd | Antiimalignant tumor agent composition |
| JPS5564518A (en) * | 1978-11-07 | 1980-05-15 | Taiho Yakuhin Kogyo Kk | Carcinostatic composition |
| DE3665260D1 (en) * | 1985-05-07 | 1989-10-05 | Teijin Ltd | Antitumor agent |
| JPS61291595A (ja) * | 1985-06-19 | 1986-12-22 | Ajinomoto Co Inc | ２′−ｏ−メチル化ｒｎａの製造法 |
| JPS6214794A (ja) * | 1985-07-09 | 1987-01-23 | Ajinomoto Co Inc | 発酵法によるグアノシン及び／またはイノシンの製造法 |
| JPS6223725A (ja) | 1985-07-24 | 1987-01-31 | Sekisui Plastics Co Ltd | 熱可塑性樹脂発泡体の製造装置 |
| JPS6223723A (ja) | 1985-07-24 | 1987-01-31 | Canon Inc | 射出圧縮成形方法 |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| JPH01125325A (ja) * | 1987-11-11 | 1989-05-17 | Agency Of Ind Science & Technol | 抗腫瘍剤 |
| JP2926409B2 (ja) * | 1989-05-22 | 1999-07-28 | 株式会社林原生物化学研究所 | 癌転移抑制因子の製造方法 |
| US5200514A (en) | 1990-01-19 | 1993-04-06 | University Of Georgia Research Foundation, Inc. | Synthesis of 2'-deoxypyrimidine nucleosides |
| JPH0695946B2 (ja) * | 1991-01-23 | 1994-11-30 | 日本製紙株式会社 | ウリジンの製造法 |
| US5580973A (en) * | 1994-01-07 | 1996-12-03 | Lee-Ruff; Edward | Process for preparing optically active nucleosides from chiral cyclobutanones |
-
1998
- 1998-06-02 CN CNB2004100789678A patent/CN1292073C/zh not_active Expired - Lifetime
- 1998-06-02 CA CA002294158A patent/CA2294158C/en not_active Expired - Lifetime
- 1998-06-02 AU AU75490/98A patent/AU754370B2/en not_active Ceased
- 1998-06-02 US US09/424,990 patent/US6498149B1/en not_active Expired - Lifetime
- 1998-06-02 ES ES98923089T patent/ES2194320T3/es not_active Expired - Lifetime
- 1998-06-02 JP JP50205499A patent/JP3193061B2/ja not_active Expired - Fee Related
- 1998-06-02 WO PCT/JP1998/002438 patent/WO1998055493A1/ja not_active Ceased
- 1998-06-02 CN CNB988065320A patent/CN1195769C/zh not_active Expired - Lifetime
- 1998-06-02 EP EP98923089A patent/EP0997473B1/en not_active Expired - Lifetime
- 1998-06-02 KR KR10-1999-7011285A patent/KR100404630B1/ko not_active Expired - Fee Related
- 1998-06-02 DE DE69813231T patent/DE69813231T2/de not_active Expired - Lifetime
- 1998-06-02 RU RU2000100373/14A patent/RU2205010C2/ru not_active IP Right Cessation
- 1998-06-02 AT AT98923089T patent/ATE236922T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1029121A1 (en) | 2001-03-23 |
| DE69813231D1 (de) | 2003-05-15 |
| EP0997473A4 (en) | 2001-01-03 |
| JP3193061B2 (ja) | 2001-07-30 |
| EP0997473B1 (en) | 2003-04-09 |
| CN1292073C (zh) | 2006-12-27 |
| KR20010029544A (ko) | 2001-04-06 |
| CN1616671A (zh) | 2005-05-18 |
| EP0997473A1 (en) | 2000-05-03 |
| ATE236922T1 (de) | 2003-04-15 |
| CA2294158C (en) | 2004-11-23 |
| CN1195769C (zh) | 2005-04-06 |
| CN1261372A (zh) | 2000-07-26 |
| RU2205010C2 (ru) | 2003-05-27 |
| DE69813231T2 (de) | 2003-12-04 |
| WO1998055493A1 (fr) | 1998-12-10 |
| AU754370B2 (en) | 2002-11-14 |
| KR100404630B1 (ko) | 2003-11-07 |
| HK1077847A1 (en) | 2006-02-24 |
| CA2294158A1 (en) | 1998-12-10 |
| AU7549098A (en) | 1998-12-21 |
| US6498149B1 (en) | 2002-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES8206488A1 (es) | Un procedimiento para preparar compuestos de purina y piri- midina | |
| BR9916790A (pt) | Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente | |
| CA2290918A1 (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
| ES2044836T3 (es) | Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene. | |
| HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
| FI906204A0 (fi) | Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi | |
| EA200200708A1 (ru) | Производные бензазола и их применение в качестве модуляторов jnk | |
| PT928788E (pt) | Compostos farmaceuticamente activos | |
| CA2014545A1 (en) | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
| CA2238875A1 (en) | Tri-aryl ethane derivatives as pde iv inhibitors | |
| DK0437030T3 (da) | Anvendelse af 4-substituerede imidazoler til nedsættelse af det intraoculære tryk | |
| KR890003382A (ko) | 항 비루스성 화합물 | |
| EA200000431A2 (ru) | Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| ES2194320T3 (es) | Sustancias naturales antivirales o antitumorales y uso de las mismas. | |
| MD1560F2 (en) | Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses. | |
| ATE56006T1 (de) | Succinimide derivate, herstellung und anwendung. | |
| KR890005088A (ko) | 4- 아미노피리딘 유도체 및 그의 산 부가염 | |
| ES2046641T3 (es) | Composicion antitumoral. | |
| BRPI9916820B8 (pt) | composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método | |
| CA2107485A1 (fr) | Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| EP0186023A3 (en) | Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them | |
| DK601683D0 (da) | Dialkylaminoalkoxybenzylalkoholderivater | |
| DK0911026T3 (da) | Creatinderivater for astma | |
| ATE50248T1 (de) | Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung. | |
| ES2128313T3 (es) | Naftalimidas n-substituidas, su obtencion y empleo. |